- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01826708
Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations
December 30, 2014 updated by: University Hospital, Montpellier
Development of a Technique to Identify New Genes by Studying and Cloning the Breakpoints of de Novo Apparently Balanced Chromosomal Translocations in Patients Presenting With Syndromic Psychomotor Retardation
For every child with developmental delay, the investigators do a constitutional karyotype.
This karyotype can reveal an apparently balanced chromosomal rearrangement (no visible loss or gain of genetic material), such as a translocation between two or more chromosomes of accidental occurrence (not transmitted by parents).
However, an apparently balanced translocation does not explain the phenotype of the child.
Among the hypotheses that could explain the child's symptoms, there is the possibility of another chromosomal abnormality at the translocation breakpoints, another defect elsewhere on the chromosomes or gene disruption at or near the breakpoints.
Because the resolution of a constitutional karyotype is limited, these microanomalies can go undiagnosed.
The goal of this study is to look for a microanomaly on a chromosome using a technology of higher resolution than that of the conventional karyotype.
The proposed study uses DNA microarray technology on DNA extracted from blood lymphocytes to perform high-resolution analysis of all chromosomes to search for an unbalanced microrearrangement (such as loss or gain of chromosomal material).
If no microrearrangement is found, the investigators will pursue by looking for a gene disruption defect at or near the breakpoints involved in the translocation.
This will be done by first isolating the chromosomes involved in the translocation by flow cytometry and then hybridizing each of the isolated chromosomes on a new microarray.
The purpose of this study is to find a possible cause to explain the phenotype (microrearrangement or gene disruption).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Psychomotor delay is observed in approximately 3% of the general population and has various causes: environmental, genetic (gene or chromosome) or unknown.
Chromosomal abnormalities have been identified in 15% of syndromic psychomotor delay (ie.
associated with another symptom).
Balanced chromosomal translocations are observed in one out of every 1000 individuals and only 6% of patients with de novo apparently balanced translocations have an abnormal phenotype (Warburton, 1991).
Review of the literature, concerning the microarray analysis of de novo apparently balanced translocations in patients with psychomotor delay, reveals:* in 40% of cases: an abnormality not identified on the karyotype, either at the translocation breakpoints or at a different location on the genome,* in 60% of cases: no abnormalities are found with a resolution of up to 25kb (Schluth-Bolard et al., 2009).
The technique generally used to clone a breakpoint and identify a disrupted gene is a "walk" on the chromosome.
This technique uses fluorescent probes, such as BACs or PACs, located on the derivative chromosomes on both sides of the breakpoints.
This technique is labor-intensive, time-consuming and expensive because one must probe along the derivative chromosomes, closer and closer to the breakpoint, in order to find the probe overlapping the breakpoint.
The investigators propose an original, innovative and quick technique to map chromosome translocation breakpoints in patients with psychomotor delay and no abnormalities on microarray analysis.
The main aim is to develop a technique to identify new genes by cloning and mapping chromosome translocation breakpoints.
These genes would then be candidate to explain the phenotype of the patient.The study covers a 24 month period and includes 10 patients.
The feasibility of the technique, as well as its application to routine laboratory diagnosis, will be evaluated.
The study was approved by our local Bioethics Committee and respects french law of bioethics.Methodology:Patients well be selected during staff meetings including clinicians and biologists.
An initial microarray analysis well be performed to identify a gain or loss of genetic material.
Samples for which no gain or loss is identified well then undergo flow cytometry to isolate the derivative chromosomes.
Each derivative chromosome well then be hybridised to a new microarray, thus revealing the breakpoint.
The breakpoints will be confirmed by FISH technique and molecular biology techniques well be applied to clone and sequence the breakpoints.
Databases well be used to check for genes located in or around the breakpoints.
Required information: Administrative data (3 first letters of the last name and 2 first letters of the first name, date of birth, identification of parents, informed consent).
Clinical and biological data (phenotype, karyotype, other genetic studies).
Expected results: Development of rapid and less expensive technique to clone translocation breakpoints, Identification of genes potentially involved in mental delay and anomalies of embryo development, Evaluation of the distribution of various causes of syndromic mental delay (unbalanced translocation on microarray, additional rearrangement on microarray, gene disruption, or unidentified cause).
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Montpellier, France, 34295
- Laboratory of Chromosomal Genetics - Universitary Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patient with syndromic psychomotor delay
- patient with a apparently balanced de novo chromosomal translocation
- patient with health insurance
- informed consent signed by patient or by parents or by the legal representative for children
Exclusion Criteria:
- patient with an inherited translocation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Psychomotor retardation syndromic
Psychomotor retardation syndromic by Identification of breakpoints
|
Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the proportion of cases for which a cause explaining the phenotype is found for patients with a apparently balance de novo translocation
Time Frame: 6 months and 2 years
|
Evaluation of the proportion of cases for which a cause explaining the phenotype is found for patients with a apparently balance de novo translocation
|
6 months and 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jacques MD Puechberty, PHD, Laboratory of Chromosomal Genetics - Universitary Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
January 1, 2013
Study Completion (Anticipated)
April 1, 2015
Study Registration Dates
First Submitted
March 29, 2012
First Submitted That Met QC Criteria
April 3, 2013
First Posted (Estimate)
April 8, 2013
Study Record Updates
Last Update Posted (Estimate)
December 31, 2014
Last Update Submitted That Met QC Criteria
December 30, 2014
Last Verified
April 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UF 8688
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Balanced Chromosomal Translocation
-
Reproductive Medicine Associates of New JerseyCompletedBalanced Chromosomal TranslocationUnited States
-
The University of Hong KongHong Kong Young Women's Christian Association; Aberdeen Kai-fong Welfare Association...Recruiting
-
Eye & ENT Hospital of Fudan UniversityUnknownBalanced Anesthesia | Adjuvants,AnesthesiaChina
-
National Yang Ming UniversityEnrolling by invitationElectroencephalography | Electromyography | BalancedTaiwan
-
Swansea UniversityBeneo GmbHNot yet recruitingA Randomised Counter-balanced Intervention Study in Endurance Athletes
-
European HospitalUnknownEmbryo's Genetic and Chromosomal QualityItaly
-
Seoul National University HospitalCompletedStabilizing Hypnotic Depth and Vital Sign During Balanced AnesthesiaKorea, Republic of
-
Baxter Healthcare CorporationCompleted
-
Hacettepe UniversityCompleted
-
University Hospital Schleswig-HolsteinCompletedBalanced AnesthesiaGermany
Clinical Trials on Identification of breakpoints
-
EDUARDO ALBENIZInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Fundació... and other collaboratorsRecruitingGastric Cancer | Gastric Neoplasms | Gastric LesionSpain
-
Rigshospitalet, DenmarkNot yet recruiting
-
Centre Hospitalier Universitaire, AmiensRecruitingCleft Lip and PalateFrance
-
Centre integre universitaire de sante et de services...CompletedNeurocognitive Disorders | Alzheimer Disease | Primary Progressive AphasiaCanada
-
Instituto Tecnologico y de Estudios Superiores...CompletedInfant Newborn DiseaseMexico
-
Assistance Publique - Hôpitaux de ParisLaboratory of normal and pathological development Immune System - IFR 94... and other collaboratorsCompleted
-
Meyer Children's Hospital IRCCSActive, not recruitingCytopeniaItaly, United States, Belgium
-
Beijing Tiantan HospitalCompleted
-
SMG-SNU Boramae Medical CenterNot yet recruitingCricothyroid Membrane
-
Hillel Yaffe Medical CenterUnknown